EA
PCRX icon

Emerald Acquisition’s Pacira BioSciences PCRX Stock Holding History

Emerald Acquisition’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$440K Sell
12,860
-2,413
-16% -$94.5K ﹤0.01% 2487
2016
Q2 		$515K Buy
+15,273
New +$751K ﹤0.01% 2460

Other funds holding PCRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Emerald Acquisition's PCRX Position: Q3 2016 in Review

Emerald Acquisition reduced its Pacira BioSciences (PCRX) stake by 16% in Q3 2016, selling an estimated $94.5K and leaving 12,860 shares worth $440K. The position accounts for ﹤0.01% of the portfolio, ranked #2487.

Emerald Acquisition first reported a position in PCRX in Q2 2016 and has held it in 2 quarters since. The position peaked at $515K in Q2 2016. 180 funds tracked by Wall St. Rank hold PCRX as of Q3 2016.

  • Emerald Acquisition held 12,860 shares of Pacira BioSciences worth $440K as of Q3 2016.
  • Emerald Acquisition sold 2,413 Pacira BioSciences shares in Q3 2016, an estimated $94.5K.
  • Pacira BioSciences made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2487 holding.
  • Emerald Acquisition first reported a position in Pacira BioSciences in Q2 2016 and has held it in 2 quarters since.
  • Emerald Acquisition's Pacira BioSciences position peaked at $515K in Q2 2016.
  • 180 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.